Skip to main content

Duvelisib News

FDA Medwatch Alert: Drug Safety Communication: Copiktra (duvelisib) - FDA Warns about Possible Increased Risk of Death and Serious Side Effects

ISSUE: The FDA is warning that results from a clinical trial show a possible increased risk of death with Copiktra (duvelisib) compared to another medicine to treat a chronic blood cancer called...

FDA Approves Copiktra (duvelisib) Capsules for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma

BOSTON--(BUSINESS WIRE)--Sep. 24, 2018-- Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma

Duvelisib patient information at Drugs.com